Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Codagenix Inc. is managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, meaning the company is interacting with a different individual for each of its pending matters. This distribution provides a range of examiner feedback across the active portfolio.
The matters are situated within 2 distinct art units, suggesting that while the examiners differ, the technical focus remains concentrated in specialized areas. CHESTNUT, BARRY A is the busiest examiner, currently overseeing 1 pending office action. Since the busiest examiner pending count is 1, all the pending office actions are spread across the examiners. For the practitioner, this means that while different people are reviewing the applications, they are doing so within only 2 distinct art units. This requires a strategy that is consistent with the standards of those departments while being persuasive to the different individuals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572482 | DEOPTIMIZED YELLOW FEVER VIRUS AND METHODS AND USES THEREOF | KINSEY WHITE, NICOLE ERIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17621125 | ATTENUATED DENGUE VIRUSES | CHEN, STACY BROWN | 24d overdue |
| 18690297 | FREEZE-DRIED VIRAL COMBINATION VACCINE COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF | LY, KRISTINA ELISABETH | — |
| 18572482 | DEOPTIMIZED YELLOW FEVER VIRUS AND METHODS AND USES THEREOF | KINSEY WHITE, NICOLE ERIN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 3 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18758660 | VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES | CHESTNUT, BARRY A | 1672 | §112DP | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18690297 | FREEZE-DRIED VIRAL COMBINATION VACCINE COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF | LY, KRISTINA ELISABETH | 1671 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18572482 | DEOPTIMIZED YELLOW FEVER VIRUS AND METHODS AND USES THEREOF | KINSEY WHITE, NICOLE ERIN | 1672 | §102§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 17621125 | ATTENUATED DENGUE VIRUSES | CHEN, STACY BROWN | 1672 | §112 | Final Rejection | 24d overdue | Pending | Dec 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCodagenix Inc. has 4 pending office actions as of October 2026, spread across 2 art units and 4 examiners.
Barry A Chestnut has the most, with 1 of Codagenix Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
